Articles tagged with Hepatocellular Carcinoma
This review provides a comprehensive overview of CTC detection methods, their association with HCC progression, and their role in prognostication and treatment monitoring. Studies show that the number of CTCs correlates with tumor size, grade, and overall cancer severity.
A novel ratiometric fluorescent probe was synthesized to detect native human albumin (HA) activity in patients with hepatitis B cirrhosis and hepatocellular carcinoma. Native HA activity levels were significantly higher in low albumin groups, correlating with increased severity of liver disease.
This study identifies the hsa_circ_0001726/miR-140-3p/KRAS axis as a key regulator in hepatocellular carcinoma (HCC) progression and lenvatinib resistance. The axis is involved in promoting cell proliferation and migration, and is also linked to overall survival in HCC patients.
The GALAD algorithm combines AFP, AFP-L3, and PIVKA-II for HCC detection. Combining GAAD, GALAD, or PIVKA-II with ultrasound improves diagnostic efficiency compared to recommended strategies.
Researchers at VCU Massey Comprehensive Cancer Center are exploring a new approach to treating liver cancer using immunotherapy and a newly developed drug that inhibits the MYC gene. The four-year grant aims to identify effective treatment combinations for hepatocellular carcinoma, improving patient survival rates.
Researchers at Weill Cornell Medicine have discovered a biomarker that can predict which patients with liver cancer are likely to benefit from immunotherapy. The study found that high levels of the immune-suppressing protein NBR1 may identify patients who will not respond to treatment, while lowering NBR1 levels may help shrink tumors.
A new study has found that using a higher dosage of radioembolisation treatment with yttrium-90 microspheres can improve overall survival outcomes for liver cancer patients. Patients who received this elevated dose had significantly better results, with some experiencing prolonged survival and even curative treatments.
A new algorithm, Modified Metroticket, has been developed to predict overall survival and recurrence-free survival in patients with intermediate-stage liver cancer. The tool takes into account tumour burden, biological aggressiveness, liver function, and age, and has been validated using local and international datasets.
A recent study published in Liver Cancer found that patients with diabetes mellitus and comorbid obesity are at a higher risk of liver cancer recurrence after resection. The risk is significantly higher for those with comorbid obesity, increasing by approximately 3.8 times over five years postoperatively.
A recent study found a correlation between higher anti-PD-1 autoantibody levels and lower survival rates in patients with advanced liver cancer, suggesting these autoantibodies as potential biomarkers for predicting treatment response. The discovery aims to improve treatment regimens for patients with liver cancer.
A recent study published in Gastro Hep Advances found that statin use was associated with a reduced risk of hepatocellular carcinoma (HCC). The research, conducted using data from the All of Us Research Program, suggests that lipophilic statins may be an effective strategy for chemoprevention in HCC. Patients with indications for stati...
Researchers identified a three-phase transition cycle for patients with CLD, involving inferring their liver condition, being overwhelmed, and reconstructing their life. The findings suggest a shift in importance from self-awareness to accepting the status quo over time.
Women with hepatocellular carcinoma are less likely to receive a deceased-donor liver transplant due to sex-based differences in candidate size. The study's findings highlight the need for changes in allocation policy to improve access to size-matched donor livers for smaller candidates.
Researchers explore emerging role of Graph Filtration Learning (GFL) in revolutionizing HCC imaging analysis. GFL captures complex topological features inaccessible to traditional pixel-based methods.
The Chinese College of Interventionalists has introduced a consensus statement on TACE refractoriness in hepatocellular carcinoma, providing a framework for clinicians to identify and manage the condition. This move aims to optimize treatment strategies and improve patient outcomes, particularly in China where HCC incidence is high due...
A new study by Korea University College of Medicine shows that direct-acting antivirals significantly reduce liver-related clinical outcomes and lower the risk of disease progression to cancer or cirrhosis, increasing life expectancy for patients with Hepatitis C. The treatment approach has a high effectiveness rate of 90%.
Targeting mitochondrial dysfunction and mtDNA mutations is a promising therapeutic strategy for HCC, with potential benefits including restored cellular metabolism and reduced cancer progression. Research has focused on pharmacological approaches to target the electron transport chain and AMPK-dependent pathways, offering novel treatme...
A new strategy for treating chronic hepatitis B virus infection in China advocates for early treatment of all patients with detectable HBV DNA or positive HBsAg. This approach aims to reduce liver-related diseases and improve patient outcomes.
Researchers explore various immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, as promising treatments for hepatocellular carcinoma. The review aims to overcome current limitations of targeted therapies by regulating the body's immune systems.
Despite promising results, adjuvant therapies face challenges due to a lack of universally accepted standards for treatment protocols. Future research should aim to refine patient selection criteria to maximize efficacy and minimize harm.
This paper reviews various ultrasound techniques for HCC surveillance, diagnosis, and treatment, highlighting their clinical applications and benefits. Regular monitoring with gray-scale ultrasound is recommended for high-risk patients, while Doppler ultrasound techniques provide critical information for therapeutic decisions.
Immunotherapies have revolutionized HCC treatment by enhancing the immune system's ability to recognize and destroy cancer cells. Key approaches include checkpoint inhibitors, targeted therapies, and advanced cellular immunotherapies.
Fibronogen-like protein 1 (FGL1) is involved in both liver regeneration and tumor recurrence in hepatocellular carcinoma. FGL1 activates proliferative pathways that promote cancer cell growth, while its downregulation in malignant cells may contribute to HCC development.
Senecavirus A effectively suppresses HCC cell growth in vitro and in vivo, causing cell cycle arrest and apoptosis. The study demonstrates SVA's potential as a promising new treatment for HCC without harming healthy tissues.
A recent study published in Journal of Hepatology found that over 40% of liver cancer samples harbor more than one molecular subtype, leading to a
Researchers discuss primary hepatic angiosarcoma, a rare mesenchymal liver tumor, and its poor prognosis compared to hepatocellular carcinoma. Diagnosing PHA is critical due to its similar clinical presentation to HCC.
A large international multicenter observational study showed an overall sustained virological response (SVR12) rate of 96.9% for 15,849 patients with chronic hepatitis C, despite including many patients with cirrhosis, HCC, prior treatment failure, and the use of older DAAs.
A new machine-learning model using serum fusion-gene levels predicts HCC with an accuracy of 83-91%, significantly improving upon current biomarkers like serum alpha-fetal protein. This breakthrough tool may help identify patients at risk and monitor cancer recurrence, leading to improved survival rates.
Researchers found that KITLG upregulates COL4A1, leading to increased platelet activation and portal vein tumor thrombosis in hepatocellular carcinoma. The study highlights the critical role of the KITLG-COL4A1 axis in PVTT development.
A study found that lower levels of omega-3 polyunsaturated fatty acids (PUFAs) were associated with poorer outcomes in patients with liver cirrhosis and hepatocellular carcinoma. The researchers suggest that supplementing with n-3 PUFAs may help prevent sarcopenia and improve quality of life in these patients.
Researchers found that mitochondrial GRIM19 loss induces liver fibrosis through NLRP3/IL33 activation via reactive oxygen species/NF-кB signaling. This mechanism may provide potential therapeutic approaches for preventing early-stage liver fibrosis.
Researchers developed a blood signature for identifying hepatocellular carcinoma (HCC) with metastatic traits using blood levels of alpha-fetoprotein and des-γ-carboxy-prothrombin. The signature effectively predicted HCC recurrence post-RFA, with 92% specificity and 91% sensitivity in the retrospective dataset.
The detection and management of borderline hepatic nodules, particularly those hypointense in the HBP without APHE, are critical in preventing overt hepatocellular carcinoma progression. Advances in imaging technologies have improved detection and characterization of these nodules, leading to better patient prognosis.
The study reviews various immunotherapies for HCC, including ICIs and cellular therapies, highlighting their potential in managing advanced disease and preventing recurrence. Emerging strategies like vaccine development and oncolytic virotherapy are also discussed.
A groundbreaking study published in Cancer Biology & Medicine found female recipients experience significantly better post-transplant outcomes than male counterparts. The research suggests that organ allocation should account for recipient sex, potentially leading to improved care and fairness in the process.
A multicenter retrospective cohort study found that combining entecavir with Fuzheng Huayu reduced the cumulative incidence of hepatocellular carcinoma in patients with compensated chronic hepatitis B cirrhosis. The antifibrotic property of FZHY may be attributed to its beneficial effects on this population.
A study from Medical University of Vienna reveals a new molecular signaling pathway crucial to liver cancer development, offering potential new therapeutic targets. The research also identifies the c-Jun/Fra-2 complex as essential in triggering tumour growth.
Researchers discovered two distinct subtypes of hepatocellular carcinoma (HCC) and developed a risk score model predicting patient prognosis. The study identified potential drugs associated with prognostic genes, providing a novel model for HCC treatment.
A faulty beta-catenin gene helps tumours evade immunity by stopping tumor cells releasing message-containing cargoes called exosomes. Silencing mutant-beta-catenin could be a viable therapeutic strategy to trigger immune cell infiltration and increase tumour-to-immune cell communication.
This study proposes the concept of early explosive recurrence (EER) in HCC patients, characterized by rapid intrahepatic dissemination and poor prognosis. EER is associated with distinct immune profiles and treatment responses.
A new prediction tool has been developed to identify individuals at high risk for hepatocellular carcinoma (HCC) due to alcohol-related liver disease. The nomogram uses key risk factors, including heavy drinking, age, and diabetes, to predict HCC risk with high accuracy.
A machine-learning model developed by UC Davis Health clinicians and data scientists can accurately predict the risk of developing hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). The model, which was validated on a large dataset, identified four additional risk factors a...
Recent US nationwide data reveal rising HCC incidence and mortality rates primarily affecting men and older adults. The study highlights disparities among racial/ethnic groups and underscores the need for targeted early detection, intervention, and treatment strategies to improve patient outcomes.
A study by UC Davis Health found that a single dose of BCG reduced liver tumor burden and extended the survival of mice with liver cancer. The vaccine boosted the body's immunity, leading to tumor shrinkage and improved liver function.
A research team has identified an immune biomarker that explains why some patients with hepatocellular carcinoma (HCC) fail to respond to immunotherapy. The biomarker could lead to the development of new immunotherapies by restoring an effective immune response against HCC.
Researchers identified blood proteomic markers associated with hepatocellular carcinoma (HCC) in patients with cirrhosis. The study found a set of biomarkers, including TGF-β driven mechanistic biomarkers and Myostatin and Pyruvate Kinase M2, which may stratify risk for HCC.
Korea University researchers found that perioperative radiotherapy significantly improves survival rates among HCC patients at high risk of recurrence. The study suggests that radiotherapy can reduce recurrence and improve survival in these patients, providing a significant adjuvant treatment option.
A recent study discovered a causal link between oncofoetal ecosystems and liver cancer recurrence, highlighting their potential as biomarkers for treating hepatocellular carcinoma (HCC). The research found that oncofoetal reprogramming contributes to EMT, tumour cell proliferation, and response to immunotherapy.
Recent advancements in AI, particularly deep learning and neural networks, offer significant potential for improving HCC diagnosis. Early detection of HCC is crucial, as curative treatments like surgery and liver transplant are only possible in the early stages.
This review highlights the role of single-cell sequencing in HBV-HCC research, shedding light on tumor heterogeneity and immune microenvironment dynamics. The study provides new avenues for visualizing intratumoral and intertumoral heterogeneity, monitoring tumor progression, and preventing cellular deterioration.
Researchers at UC Davis Comprehensive Cancer Center have shown that inhibiting galectin 1 protein using gene therapy can shrink liver cancer in mice, improving the anti-cancer immune response and increasing killer T cells. This approach has potential as a treatment for HCC prevention.
Scientists have developed a drug-eluting hydrogel that provides sustained, pH-dependent drug co-delivery and promotes anti-tumor immune responses, reducing tumor cell proliferation and growth. The treatment shows promise in treating hepatocellular carcinoma, with enhanced efficacy compared to traditional methods.
A new study has found that different gross subtypes of hepatocellular carcinoma (HCC) have significantly different prognoses and molecular characteristics. The study suggests that gross classification may be valuable for developing individualized diagnosis and treatment strategies for HCC, with potential implications for patient outcomes.
US-born Latinos have a higher incidence of liver cancer than foreign-born Latinos, suggesting lifestyle and cultural differences may contribute to the trend. Researchers found second and third generation Mexican Americans had a 37% and 66% higher risk of liver cancer, respectively.
A clinical trial shows that a combination of atezolizumab and bevacizumab can reduce cancer recurrence in liver cancer patients by one-third after curative-intent resection or ablation. The therapy has improved recurrence-free survival rates compared to active surveillance, offering new hope for these patients.
Researchers from Columbia University have validated GLS2's ability to promote ferroptosis in murine models. This study suggests that targeting GLS2 may be a potential therapeutic strategy against liver diseases, particularly hepatocellular carcinoma.
A study published in the Chinese Medical Journal reveals that methotrexate can be an effective treatment for liver cancer with a specific genetic mutation. The drug works by disrupting nucleotide synthesis in cancer cells, making it a promising alternative to current first-line treatments.
A new gene therapy study has identified microRNA-22 as a potential treatment for liver cancer, achieving better survival outcomes and reducing inflammation compared to the current FDA-approved drug lenvatinib. The treatment was administered via a single intravenous injection and showed no observable toxicity.
A personalized calculator helps clinicians estimate risk reduction from adjuvant TACE in HCC patients. The model identifies high-risk patients who may benefit from this treatment to prevent early recurrence.
Researchers used base editors to introduce specific combinations of activating and inactivating mutations into healthy organoids, creating realistic models for various types of cancer. This allows for further investigation into the development and treatment of cancer, with potential applications including testing new drugs.